CJC-1295 (no DAC)

$19.99

All products provided by Peptides 4 Research Canada are to be used for laboratory and academic research exclusively. None of the products or services we provide on this site are to be ingested or used on humans, animals or any therapeutic uses. Customers must comply with the Terms of Sale.

 

SKU: N/A Category:

Description

CJC-1295, a maleimido derivative of hGRF(1-29), is a synthetic human GHRH analog that selectively and covalently binds to endogenous albumin after subcutaneous administration, thereby extending its half-life and duration of action.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

CJC-1295 is an analogue of GHRH with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide. These substitutions are key in increasing the overall half life of CJC-1295.

Various experiments have been conducted to test the effectiveness of CJC-1295. The Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. The mean half life was 5.8-8.1 days and after multiple doses mean IGF-1 levels remained above baseline for up to 28 days following. No serious adverse reactions were reported in any group participating in this study. This peptide has the ability to stimulate growth hormone very significantly.

Additional information

Size

2mg